FOXP3 and myeloid sarcoma: Other investigations indicated that Tregs were dramatically reduced in stable MS patients, as characterized by “CD4+CD25+FOXP3+” [193] and “CD25, CD39, Foxp3, CTLA4, and GITR expression,” but were remarkably recovered to reasonable ranges upon severe clinical onset.